Nightingale Health will perform large-scale metabolic profiling of the Mexico City Prospective Study cohort by analysing the biomarker profiles of blood samples from a cohort of 150,000 study participants. Contracted by the Nuffield Department of Population Health at the University of Oxford, Nightingale will provide novel biomarker data to accelerate research into the chronic disease risk of Hispanic populations.

The biomarker profiles of 500,000 blood samples from UK Biobank will be analysed by Nightingale Health. The research initiative was announced at the 2018 UK Biobank Scientific Conference in London. 

Nightingale Health will analyse 40,000 blood samples from Finland’s largest biobank, THL Biobank, acting under the National Institute for Health and Welfare (THL). This initiative signifies a step towards bringing personalised medicine to Finnish healthcare. Until recently, prohibitive costs and time constraints have prevented analysis of comprehensive metabolic data from large-scale biobank collections but this process has now been ma...

  Nightingale Health has been awarded as one of the Most Innovative Biotech SMEs in Europe by EuropaBio (The European Association for Bioindustries). Nightingale’s CEO, Teemu Suna, addressed European biotech leaders and EU policy-makers at an awards ceremony held at the European Parliament.

Finnish biotech Nightingale Health has announced a pilot of its technology in the healthcare sector. The goal of the pilot, in partnership with Finnish health service provider Coronaria, is to verify that Nightingale’s service can be successfully applied within a healthcare setting. Nightingale's blood test can replace many routine blood tests currently used in healthcare (e.g. glucose tests).

Finnish biomedical startup Nightingale Health has announced CE marking for its blood biomarker analysis platform. The CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region. Nightingale’s goal is to bring dozens of biomarkers included in the analysis platform gradually available for clinical use within the next year. The obtained CE mark is a step towards the company&rsq...